Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma
Authors:
- Ginette SerreroGSGinette Serrero
- Douglas M HawkinsDHDouglas M Hawkins
- Binbin YueBYBinbin Yue
- Olga IoffeOIOlga Ioffe
- Pablo BejaranoPBPablo Bejarano
- Jeffrey T PhillipsJPJeffrey T Phillips
- Jonathan F HeadJHJonathan F Head
- Robert L ElliottRERobert L Elliott
- Katherine R TkaczukKTKatherine R Tkaczuk
- Andrew K GodwinAGAndrew K Godwin
- JoEllen WeaverJWJoEllen Weaver
- Wes E KimWKWes E Kim
Open Access
- 8 February 2012
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R26
Abstract
Introduction: GP88 (progranulin) has been implicated in tumorigenesis and resistance to anti-estrogen therapies for estrogen receptor positive (ER+) breast cancer. Previous pathological studies showed that GP88 is expressed in invasive ductal carcinoma (IDC), but not in normal mammary epithelial tissue, benign lesions or lobular carcinoma. Based on these results, the present study examines GP88 prognostic significance in association with recurrence and death risks for ER+ IDC patients. Methods: Two retrospective multi-site clinical studies examined GP88 expression by immunohistochemistry (IHC) analysis of paraffin-embedded breast tumor tissue sections from ER+ IDC patients (lymph node positive and negative, stage 1 to 3) in correlation with patients' survival outcomes. The training study established a GP88 cut-off value associated with decreased disease-free (DFS) and overall (OS) survivals. The validation study verified the GP88 cut-off value and compared GP88 prognostic information with other prognostic factors, particularly tumor size, grade, disease stage and lymph node status in multivariate analysis. Results: GP88 expression is associated with a statistically significant increase in recurrence risk for ER+ IDC patients. The training study established that GP88 3+ score was associated with decreased DFS (P = 0.0004) and OS (P = 0.0036). The independent validation study verified that GP88 3+ score was associated with a 5.9-fold higher hazard of disease recurrence and a 2.5-fold higher mortality hazard compared to patients with tumor GP88 < 3+. GP88 remained an independent risk predictor after considering age, ethnicity, nodal status, tumor size, tumor grade, disease stage, progesterone receptor expression and treatments. Conclusions: The survival factor GP88 is a novel prognostic biomarker, predictive of recurrence risk and increased mortality for non-metastatic ER+ IDC patients. Of importance, our data show that GP88 continues to be a prognostic factor even after five years. These results also provide evidence that GP88 provides prognostic information independent of tumor and clinical characteristics and would support prospective study to examine whether GP88 expression could help stratify patients with ER+ tumors for adjuvant therapy.Keywords
This publication has 35 references indexed in Scilit:
- GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsBMC Cancer, 2011
- Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in miceJournal of Clinical Investigation, 2011
- Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy SubjectsBreast Cancer: Basic and Clinical Research, 2011
- Growth Factors as Active Participants in Carcinogenesis: A PerspectiveVeterinary Pathology, 2010
- Structure dissection of human progranulin identifies well‐folded granulin/epithelin modules with unique functional activitiesProtein Science, 2008
- Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer CellsCancer Research, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Stimulation of PC Cell-Derived Growth Factor (Epithelin/Granulin Precursor) Expression by Estradiol in Human Breast Cancer CellsBiochemical and Biophysical Research Communications, 1999